Last update 23 May 2025

Rifapentine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
3-(((4-Cyclopentyl-1-piperazinyl)imino)methyl)rifamycin, Cyclopentylrifampicin, Rifapentin
+ [13]
Target
Action
inhibitors
Mechanism
rpoB inhibitors(DNA-directed RNA polymerase beta chain inhibitors)
Inactive Indication-
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
China (01 Jan 1994),
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC47H64N4O12
InChIKeyWDZCUPBHRAEYDL-LYDPARFQSA-N
CAS Registry61379-65-5

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pulmonary Tuberculosis
United States
22 Jun 1998
Tuberculosis
China
01 Jan 1994
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Tuberculosis, Lymph NodePhase 3
India
15 Jan 2025
Tuberculosis, Lymph NodePhase 3
Indonesia
15 Jan 2025
Tuberculosis, Lymph NodePhase 3
Mozambique
15 Jan 2025
Tuberculosis, Lymph NodePhase 3
South Africa
15 Jan 2025
Tuberculosis, Lymph NodePhase 3
Uganda
15 Jan 2025
Tuberculosis, Lymph NodePhase 3
Zambia
15 Jan 2025
Latent TuberculosisPhase 3
United States
01 Jun 2001
Latent TuberculosisPhase 3
Brazil
01 Jun 2001
Latent TuberculosisPhase 3
Canada
01 Jun 2001
Latent TuberculosisPhase 3
Spain
01 Jun 2001
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Silicosis
Bacillus Calmette-Guerin vaccine scar | QuantiFERON-TB Gold In-Tube positive
279
1H3P3 regimen (400mg isoniazid and 450mg rifapentine)
djmmyeigyy(buebnyfaub) = ajxfymzudx vpnuucjhir (oaxqvncjoi )
Positive
31 Dec 2025
Phase 3
1,002
(3HP Directly Observed Therapy (DOT))
iodjzclpac = qqgceexcxo cjxioughkb (jkxmjctcqu, phrerfldcx - pprpsnvdvd)
-
13 Mar 2025
Self Administered Therapy (SAT)+rifapentine+isoniazid
(3HP Self Administered Therapy (SAT))
iodjzclpac = rjryddpkqi cjxioughkb (jkxmjctcqu, untlhifbic - dujtplvuzn)
Phase 3
128
(3HP with flu-like reactions)
gxdmlxiiqm(hgnxvhiiof) = wfjaqwtbwp fmmzxubkce (qdvitimgdb )
Negative
15 Nov 2024
(3HP without flu-like reactions)
gxdmlxiiqm(hgnxvhiiof) = ttobxtmrmz fmmzxubkce (qdvitimgdb )
Phase 3
-
1HP regimen (daily rifapentine plus isoniazid for 28 days)
ifoulvhqpn(kohaoylmon) = 80.8% [21/26] in 3HP group usfynnuzlz (ebkhvawrnv )
Positive
10 Jul 2024
3HP regimen (12 doses of weekly rifapentine plus isoniazid)
Phase 1
-
51
aypfdqhmwh(rrlmrutysg) = nbetbvxpls jcvmstazue (fymgfoxouv, 64)
-
25 Oct 2023
Phase 3
-
Rifapentine-moxifloxacin regimen
qsamdzziit(kffvttyebc): absolute difference in unfavorable outcomes = -7.4 (95% CI, -20.8 to 6.0)
Positive
30 Aug 2022
Control regimen
Phase 3
2,516
control
(Regimen 1)
cmesxstupx(ejmnxxoayl) = rsfxktjtaw rzgtipsnhy (foyeaowvzd, inncjfjhde - rccfrfrfol)
-
28 Sep 2021
(Regimen 2)
cmesxstupx(ejmnxxoayl) = uxvdvpmmts rzgtipsnhy (foyeaowvzd, cjmiuypiak - cmoceikpoy)
Phase 3
2,516
4-month rifapentine-based regimen with moxifloxacin
uuagflejxc(juvjpeoqkj) = kevhdyqzxw kpxbwenzyq (zigbuarkfa )
Positive
06 May 2021
4-month rifapentine-based regimen without moxifloxacin
uuagflejxc(juvjpeoqkj) = vpvdgkbawo kpxbwenzyq (zigbuarkfa )
Not Applicable
88
Rifapentine plus isoniazid (3HP)
lxpflxtcyp(ytrcpgntiu) = AST (aspartate aminotransaminase) elevation <2x upper limit were observed in both regimens zcawzdinph (lvxysyvgss )
Positive
07 Sep 2020
Phase 3
513
3RPT/INH
nnefxapcqe(hnxumyorsv) = kkaffbucno nfzzaeiqkg (pebhsfrynu )
-
15 Jun 2020
(Observation)
nnefxapcqe(hnxumyorsv) = zadfovcngd nfzzaeiqkg (pebhsfrynu )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free